A Eirin

A Eirin

A Eirin
Executive Editor
Assistant Professor of Medicine, Mayo Clinic in Rochester
Minnesota, USA


I am an Assistant Professor of Medicine currently working at Mayo Clinic in Rochester, Minnesota. I graduated the School of Medicine at the University of the Republic, Montevideo, Uruguay in 2004. I was involved in clinical practice in Montevideo until December of 2008, when my interest in research drove me to the Mayo Clinic to work as a Research Trainee, Research Fellow, and Senior Research Fellow in the Division of Nephrology and Hypertension. Over the past years, I have published more than 40 peer-reviewed papers and more than 60 abstracts in prestigious scientific journals in the field of renal and cardiovascular diseases, 3 book chapters, and served as a reviewer for several peer-reviewed journals with a worldwide circulation, such as Hypertension and Circulation. I have also presented multiple oral and poster presentations at recognized scientific meetings such as the American Society of Nephrology Renal Week, which is the world’s premier nephrology meeting. I have received several awards including a 2-years postdoctoral fellowship from the American Heart Association (2010-2012), the “Outstanding Research Fellow Award 2012” from the Department of Medicine at Mayo Clinic, a Training & Career Development Award from the Center for Regenerative Medicine at Mayo Clinic, a “Top Oral Abstract by Trainees for the ASN Kidney Week 2012”, the “Top Scoring abstract in all 16 American Heart Association’s Specialty Conferences 2012”.

Research Interest

My research interests have focused on understanding the pathogenesis of renal and cardiac injury due to atherosclerotic renovascular disease (ARVD), and the development of novel treatment strategies to improve blood pressure and renal outcomes after revascularization in swine ARVD. These studies include the application of state-of-the-art imaging techniques (multi-detector computer tomography, micro-computer tomography, magnetic resonance imaging, etc.) in animal models and in humans. In addition, I have been involved in several projects aimed to elucidate the deleterious effects of inflammation in the ARVD kidney, and the development of treatment options (stem cells, progenitor cells, anti-apoptotic drugs, etc.) to attenuate microvascular rarefaction and loss beyond the stenotic lesion.